Tranexamic Acid vs Kojic Acid for Melasma Treatment: A Formulation Science Comparison

Tranexamic Acid vs Kojic Acid for Melasma Treatment: Mechanisms, Efficacy, and Formulation Considerations

When formulating a targeted treatment for melasma, the choice between tranexamic acid vs kojic acid for melasma treatment is one of the most consequential decisions a cosmetic chemist can make. Both ingredients are established skin-brightening actives with distinct mechanisms of action, yet they operate at fundamentally different points in the pigmentation cascade. Understanding these differences is critical to designing effective, stable formulations that deliver real clinical results.

Mechanism of Action: Two Fundamentally Different Approaches

How Tranexamic Acid Suppresses Pigmentation

Tranexamic acid (TXA) is a synthetic lysine analog (CAS 1197-18-8, MW 157.21) originally developed as an antifibrinolytic agent. Its application in dermatology emerged from the observation that it reduces melanogenesis through a unique upstream mechanism: the plasminogen/plasmin pathway.

Here is how it works step by step:

• UV exposure and inflammation activate keratinocytes, which release urokinase-type plasminogen activator (uPA)
• uPA converts plasminogen (derived from dermal vasculature) into plasmin in the basal epidermis
• Plasmin stimulates the release of pro-melanogenic mediators including arachidonic acid, prostaglandin E2, and alpha-melanocyte stimulating hormone (α-MSH)
• TXA competitively binds to lysine-binding sites on plasminogen, blocking its conversion to plasmin and thereby interrupting the entire signaling chain before melanocytes are stimulated

Additional mechanisms have been identified. A 2024 study by Lei et al. demonstrated that TXA downregulates endothelin-1 (ET-1) expression in dermal microvascular endothelial cells, further reducing melanocyte proliferation. Cho et al. (2017, Journal of Dermatological Science) showed that TXA activates the autophagy system in melanocytes, providing an intracellular degradation pathway that reduces melanosome formation. Together, these three mechanisms explain why TXA is particularly effective against the vascular and inflammatory components of melasma—the very features that distinguish melasma from simple hyperpigmentation.

Topical TXA is typically used at 2–5% in serums and creams. It is water-soluble, stable across a pH range of 5.0–7.0, and compatible with most common cosmetic ingredients. Its molecular weight of 157 Da allows reasonable epidermal penetration, though penetration enhancers or delivery systems can improve dermal bioavailability.

How Kojic Acid Inhibits Melanin Synthesis

Kojic acid (CAS 501-30-4, MW 142.11) is a fungal metabolite produced by Aspergillus oryzae during the fermentation of rice. Unlike TXA, kojic acid works directly at the enzymatic level by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis.

The mechanism is straightforward: kojic acid chelates the copper ions at the active site of tyrosinase, preventing the enzyme from catalyzing the oxidation of tyrosine to DOPA and DOPA to dopaquinone. Without functional tyrosinase, melanocytes cannot produce melanin regardless of upstream signaling—this is a direct blockade rather than signal interception.

The SCCP (Scientific Committee on Consumer Products, 2008) evaluated kojic acid and concluded it is safe at concentrations up to 1% in leave-on cosmetic products. Despite this conservative regulatory limit, many commercial formulations use 1–4%, often relying on kojic acid dipalmitate (a more stable ester derivative) or encapsulation to mitigate stability concerns.

Clinical Evidence: What the Data Show

Tranexamic Acid in Melasma

The evidence base for TXA in melasma spans oral, intradermal, and topical routes. A 2023 focused review by Konisky et al. (Journal of Cosmetic Dermatology) documented that oral TXA at 250 mg twice daily produced clinically significant improvement in melasma severity in 89–94% of patients over 6 months. Topical TXA at 2–5% has been shown in multiple split-face studies to reduce MASI (Melasma Area and Severity Index) scores by 25–35% over 12 weeks, with a safety profile superior to hydroquinone—no risk of exogenous ochronosis or steroid atrophy.

Intradermal microinjection of TXA (4 mg/mL) has shown the fastest results, with visible improvement in 4–8 weeks, though this route requires clinical administration. A key finding from a 2024 mouse model study: oral TXA outperformed topical TXA in skin lightening, attributed to better suppression of ET-1 in dermal microvasculature—highlighting that topical delivery optimization remains an active area of research.

Kojic Acid in Melasma

Kojic acid has a longer history in cosmetic use and a larger volume of comparative trials against other tyrosinase inhibitors. A meta-analysis of kojic acid formulations found that 1–2% kojic acid combined with glycolic acid produced 40–55% improvement in melasma severity over 12 weeks. When used alone at 1%, the improvement was more modest (20–30%). Notably, kojic acid at 2% combined with hydroquinone 2% demonstrated efficacy comparable to hydroquinone 4% monotherapy, suggesting a synergistic role as a hydroquinone-sparing agent.

However, head-to-head studies comparing TXA and kojic acid directly remain limited. The available evidence suggests that TXA is superior for vascular-inflammatory melasma (the most common clinical subtype), while kojic acid performs well in epidermal pigmentation without a strong vascular component.

Tranexamic Acid vs Kojic Acid for Melasma Treatment: Formulation Considerations

Stability and Compatibility

This is where the two ingredients diverge significantly for the formulator:

• Tranexamic Acid: Excellent stability in aqueous systems. No significant photodegradation, oxidation, or pH-dependent degradation within the usable cosmetic range (pH 4.5–7.5). Compatible with niacinamide, vitamin C (L-ascorbic acid at low pH), alpha arbutin, retinoids, and most preservatives. Does not discolor over time.
• Kojic Acid: Notoriously unstable. Oxidizes readily upon exposure to air and light, turning from white/pale yellow to brown within weeks in inadequately protected formulations. Requires antioxidants (BHT, sodium metabisulfite, vitamin E), chelating agents (EDTA), opaque/airless packaging, and storage below 25°C. The discoloration is not merely aesthetic—oxidized kojic acid loses efficacy and may become a contact sensitizer.

pH Optimization

Kojic acid formulations perform best at pH 3.5–5.0, where the molecule remains protonated and its copper-chelating ability is maximal. However, this acidic range can be irritating when combined with other actives. TXA is effective at pH 5.0–7.0, making it more skin-friendly and easier to formulate in gentle, moisturizing bases suitable for the sensitive, barrier-compromised skin typical of melasma patients.

Synergy Potential

Because TXA and kojic acid target different steps in the pigmentation pathway—TXA at the signaling level (plasmin → inflammatory mediators) and kojic acid at the enzymatic level (tyrosinase)—they are mechanistically complementary. A formulation combining 3% TXA with 1% kojic acid addresses both the upstream trigger and downstream execution of melanin synthesis. Commercial products following this logic include Naturium’s Tranexamic Topical Acid 5% (which combines TXA with kojic acid, niacinamide, and licorice root) and Belo’s Intensive Whitening Bar.

When formulating such combinations, protect kojic acid with 0.1% sodium metabisulfite, use an airless pump package, and formulate at pH 5.0–5.5 as a compromise between the optimal pH ranges of both actives.

Practical Takeaways for Formulators

• Choose TXA as your primary active if targeting melasma with a visible vascular component (erythema, telangiectasia) or post-inflammatory hyperpigmentation—its anti-plasmin and anti-inflammatory mechanisms directly address the underlying pathology.
• Choose kojic acid for epidermal pigmentation without inflammation, or as a second-line tyrosinase inhibitor alongside other actives.
• Combine both for maximum efficacy across the entire pigmentation pathway, but invest in stabilization: airless packaging, antioxidants, and rigorous accelerated stability testing (40°C/75% RH for 3 months minimum).
• Delivery matters: TXA’s relatively low molecular weight (157 Da) allows passive diffusion, but pairing with penetration enhancers (ethoxydiglycol, liposomal carriers) can improve dermal targeting. Kojic acid dipalmitate offers better stability and skin penetration than free kojic acid.
• Safety first: TXA has an excellent safety profile with negligible irritation even at 5%. Kojic acid carries a higher sensitization risk—consider a 1% ceiling and always pair with soothing agents (bisabolol, allantoin, panthenol) in melasma formulations where barrier integrity is already compromised.

References

• Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023. doi:10.1111/jocd.15589
• Hiramoto K et al. Mechanism of Action of Topical Tranexamic Acid in the Treatment of Melasma and Sun-Induced Skin Hyperpigmentation. 2022. ResearchGate
• Lei TC et al. Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells. 2024. ResearchGate
• Cho YH, Park JE, Lim DS, Lee JS. Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells. J Dermatol Sci. 2017. doi:10.1016/j.jdermsci.2017.05.019
• SCCP (Scientific Committee on Consumer Products). Opinion on Kojic Acid. SCCP/1182/08. 2008. EU SCCP Opinion
• Ashooriha M et al. 1,2,3-Triazole-based kojic acid analogs as potent tyrosinase inhibitors. Bioorg Chem. 2019. ScienceDirect
• Colferai MMT, Miquelin GM, Steiner D. Evaluation of oral tranexamic acid in the treatment of melasma. J Cosmet Dermatol. 2019;18:1495-1501.
• Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012.